A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3B MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED STUDY COMPARING THE SAFETY AND EFFICACY OF UPADACITINIB TO DUPILUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Intervention/treatment:
UPADACITINIB (ABT-494)
Medical condition:
ATOPIC DERMATITIS
Protocol code:
M16-046
Control number:
222446
Status:
Closed
Approved:
December 19, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03738397
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 76 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Medical Services
Organization
AbbVie
Phone:
800-633-9110
Sponsor
ABBVIE CORPORATION

Locations

Alberta

Dermatology Research Institute Inc. /ID# 210942
Calgary, Alberta, T2J 7E1
Kirk Barber Research, CA /ID# 209504
Calgary, Alberta, T2G 1B1

British Columbia

Dr. Chih-ho Hong Medical Inc. /ID# 211032
Surrey, British Columbia, V3R 6A7
Enverus Medical Research /ID# 209503
Surrey, British Columbia, V3V 0C6

Ontario

DermEdge Research Inc. /ID# 211122
Mississauga, Ontario, L5H 1G9
Dr. Wei Jing Loo Medicine Prof /ID# 211400
London, Ontario, N6H 5L5
K. Papp Clinical Research /ID# 209509
Waterloo, Ontario, N2J 1C4
Lynderm Research Inc. /ID# 209505
Markham, Ontario, L3P 1X2
Niakosari Medicine Professional Corporation /ID# 211401
Toronto, Ontario, M2M 4J5

Quebec

Dre Angelique Gagne-Henley M.D. inc. /ID# 209498
Saint-Jérôme, Quebec, J7Z 7E2

Results

See the results from the trial NCT03738397. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?